AACR Annual Meeting 2026: Chinese Clinical Trials Scheduled for Presentation
More than 40 clinical trial abstracts from primary authors based in China were submitted for presentation at the AACR Annual Meeting 2026. We thank our colleagues in China for considering the AACR Annual Meeting as a presentation forum for their paradigm-shifting work.
The full text of clinical trial abstracts are embargoed until 3:00 PM ET on Friday, April 17. Upon release, the abstract text will be available through the online program planner, which can be accessed by clicking on the abstract numbers below.
Clinical Trials Plenary Session: Therapeutic Advances in ADCs
Sunday, April 19; 3:30-5:30 p.m.; Hall H
Abstract CT036: A first-in-human study result of a novel EGFR-targeted antibody drug conjugate (ADC) in patients with advanced nasopharyngeal carcinoma (NPC) (SYS6010-001-NPC)
Haiqiang Mai, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China
Abstract CT037: A first-in-human phase 1 trial of a novel claudin 6 (CLDN6)-targeting antibody drug conjugate (ADC) QLS5132 in patients (pts) with platinum-resistant ovarian cancer (PROC)
Tao Zhu, Zhejiang Cancer Hospital, Hangzhou, China
Abstract CT038: Combination of risvutatug rezetecan and adebrelimab in previously treated advanced nsq-NSCLC without actionable genomic alterations: Results from ARTEMIS-101, a phase 1 study
Runbo Zhong, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Clinical Trials Minisymposium: Aiming for Cure—Perioperative Clinical Trials
Saturday, April 18; 12:30-2:30 p.m.; Ballroom 6 A
Abstract CT014: Perioperative adebrelimab (A) plus chemotherapy (chemo) in resectable stage II-III NSCLC: Phase 3 EFS interim analysis (IA) and molecular residual disease (MRD) analysis
Yi-Long Wu, Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
Clinical Trials Minisymposium: Advanced Cellular and Immune-Based Therapeutics
Sunday, April 19; 3-5 p.m.; Ballroom 20 AB
Abstract CT027: Safety and preliminary efficacy of a novel LACO-Stim armored mesothelin-targeted CART therapy in advanced solid tumors
Changsong Qi, Peking University Cancer Hospital & Institute, Beijing, China
Abstract CT032: ABO2203, a messenger RNA encoding a CD3×CD19 T cell engager, for relapsed/refractory B cell non-Hodgkin lymphoma: Preliminary results from first-in-human study
Li Wang, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
Clinical Trials Minisymposium: Advances in Precision Oncology
Tuesday, April 21; 2:30-4:30 p.m.; Hall H
Abstract CT299: Dirozalkib versus crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): Results from the multicenter, randomized, open-label phase 3 trial
Haifeng Liu, Department of Oncology, Jilin Provincial Cancer Hospital, Changchun, China
Abstract CT301: SHR-A1811 ± adebrelimab as first-line (1L) treatment for advanced HER2-mutant NSCLC: A randomized phase 2 cohort from a phase 1b/2 study
Shun Lu, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Abstract CT302: The safety, tolerability, and efficacy of HS-10504 in patients with EGFR mutation-positive locally advanced or metastatic NSCLC: Initial results from a first-in-human phase 1 study
Zhanhong Xie, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Poster Session: Phase II and Phase III Clinical Trials
Monday, April 20; 2-5 p.m.; Poster Section 52
Abstract CT145: A phase II, multicenter, open-label study (COMPASSION-26) of cadonilimab, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy (chemo) as first-line therapy for advanced pancreatic ductal adenocarcinoma (PDAC)
Xiafei Hong, Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, China
Abstract CT146: Sequential treatment with surufatinib combined with gemcitabine and nab-paclitaxel (AG) or AG alone as first-line therapy for locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC) after 6 weeks of AG induction therapy: A two-cohort, exploratory phase II study
Jialin Li, Fudan University Shanghai Cancer Center, Shanghai, China
Abstract CT150: Sintilimab plus cisplatin and nab-paclitaxel induction treatment for locally advanced borderline resectable esophageal squamous cell carcinoma: A single-arm, prospective, phase 2 study (NEOCRTEC2001)
Xin Zhang, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China
Abstract CT151: CDK4/6 inhibitor dalpiciclib combined with mFOLFOX6 in pretreated metastatic colorectal cancer: Results from a Simon two-stage phase II study
Xiaoyu Xie, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Abstract CT152: Preliminary results from a phase II trial evaluating the safety and efficacy of JS207, a bispecific antibody targeting PD-1 and VEGF, in combination with chemotherapy in patients with metastatic colorectal cancer
Yong Gao, Shanghai East Hospital, Shanghai, China
Abstract CT159: JS207, a bispecific antibody targeting PD-1 and VEGF-A, combined with JS007 (anti-CTLA4), for patients with advanced hepatocellular carcinoma in a randomized, multicenter, Phase II study
Jian Zhou, Zhongshan Hospital, Fudan University, Shanghai, China
Abstract CT160: Updated multicenter phase Ib/II analysis of surufatinib plus sintilimab and capecitabine in previously treated metastatic small bowel adenocarcinoma and appendiceal carcinoma
Xiaoyu Xie, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Poster Session: Phase II Clinical Trials
Tuesday, April 21; 2-5 p.m.; Poster Section 50
Abstract CT239: Neoadjuvant adebrelimab plus chemotherapy in untreated locally advanced head and neck squamous cell carcinoma: Efficacy and biomarker insights from a single-arm phase II trial
Ruihua Fang, The First Affiliated Hospital Sun Yat-Sen University, Guangzhou, China
Abstract CT242: Covalent FAPI imaging-guided precision surgery in medullary thyroid carcinoma
Ziren Kong, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
Abstract CT243: Dirozalkib in patients with advanced ALK-positive non-small cell lung cancer (NSCLC): Results from a phase 2 study
Haifeng Liu, Department of Oncology, Jilin Provincial Cancer Hospital, Changchun, China
Abstract CT247: Savolitinib combined with Durvalumab in EGFR wild-type advanced NSCLC patients with MET alterations (SOUND): A multicenter, open-label, Phase II trial
Yong-Feng Yu, Department of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Poster Session: Phase I Clinical Trials
Tuesday, April 21; 9 a.m.-12 p.m.; Poster Section 50
Abstract CT180: Safety and efficacy of pucotenlimab combined with standard chemotherapy regimens in the preoperative treatment of pediatric patients with intermediate or high-risk rhabdomyosarcoma: A phase I/II study
Yizhuo Zhang, Sun Yat-sen University Cancer Center (SYSUCC), Guangzhou, China
Abstract CT192: The first report of patients with solid tumors treated with LP-118, a novel Bcl-2/Bcl-xL dual inhibitor
Qing Zhou, Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
Abstract CT195: Fast-manufactured, low IL-2-dependent FAST-TIL for the treatment of advanced melanoma in asian patients: Median 6-month follow-up data from a phase I clinical trial
Xinhua Zhang, Huasai Biomedicine Co., Ltd., Hangzhou, China
Poster Session: First-in-Human Phase I Clinical Trials
Monday, April 20; 9 a.m.-12 p.m.; Poster Section 50
Abstract CT049: ACR246, a novel anti-5T4 antibody-drug conjugate: Updated phase I/IIa study results in advanced solid tumors
Zhenwei Miao, Hangzhou Adcoris Biopharma Co., Ltd., Hangzhou, China
Abstract CT057: Preliminary results from the first-in-human study of MK-2010, a PD-1×VEGF bispecific antibody
Jin Li, Shanghai GoBroad Cancer Hospital, China Pharmaceutical University, Shanghai, China
Abstract CT060: First in human phase 1 study of D3S-002, a purposely designed ERK1/2 inhibitor, in advanced solid tumors with MAPK pathway mutations
Shaonan Wang, D3 Bio Inc., Shanghai, China
Abstract CT061: A phase I study of the type II ROS1 TRK inhibitor ANS03 in ROS1 fusion-positive lung cancers
Shengxiang Ren, Shanghai Pulmonary Hospital, Shanghai, China
Abstract CT064: Updated results from a first-in-human phase 1,2 study of ACE-106, a highly selective and potentially best-in-class PARP1 inhibitor in advanced solid tumors
Xingyun Cai, Acerand Therapeutics (Hong Kong) Limited, Shanghai, China
Poster Session: Phase 0 and First-in-Human Phase I Clinical Trials
Monday, April 20; 2-5 p.m.; Poster Section 51
Abstract CT115: LYC001, a high-affinity hierarchical assembly for lymph node-targeted IL-2 immunotherapy: Preclinical validation of potent antitumor immunity and preliminary safety from the first-in-human phase Ia study
Wenfeng Zeng, LiangYuan Bioscience, LLC, Beijing, China
Abstract CT117: Phase 1 study of HRS-6209, a highly selective CDK4 inhibitor, in patients with advanced solid tumors
Jiong Wu, Fudan University Shanghai Cancer Center, Shanghai, China
Abstract CT122: First-in-human (FIH) study of EVM16, a personalized mRNA neoantigen vaccine, as monotherapy and combination with tislelizumab in advanced solid tumors
Lin Shen, Beijing Cancer Hospital, Beijing, China
Abstract CT127: First-in-human study of ES014, a bispecific antibody targeting CD39 and TGF-β as monotherapy in patients with advanced solid tumors
Yehua Zhu, Elpiscience Biopharma, Ltd., Shanghai, China
Abstract CT128: Preliminary results from a first-in-human phase I/II study of JS212, an EGFR/HER3-targeted bispecific antibody-drug conjugate (ADC), in patients with advanced solid tumors
Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
Poster Session: Phase II and Phase III Clinical Trials in Progress
Tuesday, April 21; 9 a.m.-12 p.m.; Poster Section 51
Abstract CT212: Neratinib efficacy in second line patients with EGFR exon 18-mutant non-small-cell lung cancer
Steve Shen, Convalife Pharmaceuticals Co., Ltd., Shanghai, China
Poster Session: Phase I and Phase II Clinical Trials in Progress
Tuesday, April 21; 2-5 p.m.; Poster Section 51
Abstract CT288: First-in-human study of oral PARG inhibitor SYN608 in advanced solid tumors
Xuzhen Tang, Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd, Hangzhou, China
Abstract CT289: Phase Ib study of POLQ inhibitor SYN818 combined with olaparib in advanced solid tumors
Xuzhen Tang, Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd, Hangzhou, China
Abstract CT290: NTS071-101: A phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of NTS071 in patients with advanced solid tumors harboring a TP53 Y220C mutation
Qiancheng Shen, Nutshell Therapeutics (Shanghai) Co., LTD., Shanghai, China
Abstract CT291: First-in-human study of the IL-12 Prodrug KGX101 demonstrates tumor-microenvironment specific activation, promising antitumor activity, and a manageable safety profile in advanced or metastatic melanoma
Lu Si, Beijng Cancer Hospital, Beijing, China
Abstract CT292: CAN016, a HER2-targeted dual-payload ADC, phase 1 clinical development
Pengqi Xu, Canwell Biotechnology Company, Guangzhou, China
Poster Session: Phase I Clinical Trials in Progress
Monday, April 20; 9 a.m.-12 p.m.; Poster Section 51
Abstract CT074: A phse 1 study of CAN2109, a novel,long-acting, tumor-retained, immunoegenic cell death inducer
Jiancheng Huang, Canwell Biotechnology Company, Guangzhou, China
Abstract CT078: First-in-human phase I study of UCL70802, a LACO-Stim armored Anti-CD70 CART cell therapy, in patients with metastatic clear cell renal cell carcinoma (mccRCC)
Yangbing Zhao, UTC Therapeutics INC., Shanghai, China
Abstract CT095: Phase I/II clinical trial of CVL006 combination therapy in advanced solid tumors
Steve Shen, Convalife Pharmaceuticals Co., Ltd., Shanghai, China
